anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Hyaluronidase is an endoglycosidase. It is a preparation of purified bovine testicular hyaluronidase, a protein enzyme. Hyaluronidase is composed of two major glycosylated forms, α and β. The exact chemical structure of this enzyme is unknown.

Amphadase® (hyaluronidase injection) is supplied as a sterile, clear and colorless, ready for use 1 mL solution in a single-dose vial for infiltration use, for interstitial use, for intramuscular use, for peribulbar use, for soft tissue use, or for subcutaneous use. Each mL contains 150 USP units of hyaluronidase with calcium chloride (0.4 mg), edetate disodium (1.0 mg), monobasic sodium phosphate (1.7 mg), sodium chloride (8.5 mg), not more than 0.1 mg thimerosal (mercury derivative), and Water for Injection, USP. Sodium hydroxide may be added to adjust pH.

Amphadase® has an approximate pH of 6.8 and an osmolality of 295 to 355 mOsm.
In modern healthcare, integrating Artificial Intelligence (AI) and Internet of Medical Things (IoMT) is highly beneficial and has made it possible to effectively control disease using networks of interconnected sensors worn by individuals. The purpose of this work is to develop an AI-IoMT framework for identifying several of chronic diseases form the patients' medical record. For that, the Deep Auto-Optimized Collaborative Learning (DACL) Model, a brand-new AI-IoMT framework, has been developed for rapid diagnosis of chronic diseases like heart disease, diabetes, and stroke. Then, a Deep Auto-Encoder Model (DAEM) is used in the proposed framework to formulate the imputed and preprocessed data by determining the fields of characteristics or information that are lacking. To speed up classification training and testing, the Golden Flower Search (GFS) approach is then utilized to choose the best features from the imputed data. In addition, the cutting-edge Collaborative Bias Integrated GAN (ColBGaN) model has been created for precisely recognizing and classifying the types of chronic diseases from the medical records of patients. The loss function is optimally estimated during classification using the Water Drop Optimization (WDO) technique, reducing the classifier's error rate. Using some of the well-known benchmarking datasets and performance measures, the proposed DACL's effectiveness and efficiency in identifying diseases is evaluated and compared.
PURPOSE:To obtain the titled composition, by collecting a cultivation supernatant liquid prepared by cultivating rat myofibroblastic cells liberated from rat fat tissues. CONSTITUTION:Large blood vessels are removed from fat tissues taken out of rats in a substantially germ-free state as a raw material and the residual tissues are washed and digested with a proteolytic enzyme to liberate rate myofibroblastic cells. The above-mentioned digestion solution is then centrifuged to give precipitates, which are suspended in a culture medium and filtered. The resultant fraction passing through the filter without stopping is further centrifuged and precipitated to separate and collect a component having 1,000-1,100 Percoll density from the above-mentioned precipitates. A fraction obtained by passing through a filter without stopping by filtration is cultivated. The above-mentioned cells are multiplied in a confluent state and the culture medium is exchanged several times to gather the respective supernatant liquids and afford the aimed composition containing a vascular endothelial cell growth factor. The composition is relatively readily produced and the amount sufficiently utilizable as a reagent or drug, etc., can be ensured.
Stroke is one the most common cause of mortality and disabilities in the world, with the highest incidence in East Asia. Current American Stroke Association (ASA) and European Stroke Organisation (ESO) guidelines recommend bridging therapy with IVT for all eligible patients before indicating endovascular thrombectomy (EVT) for those with large vessel occlusions (LVO). Nevertheless, the decision to use IVT on stroke patients with LVO is still debatable, with many arguments against and supporting combined therapy or direct mechanical thrombectomy. At present, guideline in our hospital advocates the use of IVT in all patients who meet eligibility criteria and present within the 4,5 hour window for anterior circulation stroke and within 24 hour window for posterior circulation stroke. Due to the overcrowded nature of our center as a high-end specialization establishment in Vietnam, it is noted that our door-to-groin time is sub-optimal. This fact inadvertently prolongs the time of action of intravenous tissue-type plasminogen activator before the re-assessment of occlusion site on interventional radiography. Therefore, it is possible for us to better estimate the reperfusion effectiveness of IVT as well as analyse other factors that might have an influence on this rate. The goal of our study is to determine the recanalization rate of IVT and related predictor factors in AIS patients.
The Briganti nomogram (cut-off value 5%) is commonly used to determine the indications for pelvic lymph node dissection (PLND) in patients with prostate cancer. We retrospectively analyzed the potential oncological benefit of PLND based on the 5% cut-off value on the Briganti nomogram. We obtained the data from the Medical Investigation Cancer Network (MICAN) Study, which included 3,463 patients who underwent a radical prostatectomy (RP) at nine institutions in Japan between 2010 and 2020. We included patients with Briganti scores ≥ 5% and a follow-up period ≥6 months and excluded patients categorized in the very high-risk group (based on NCCN categories); a final total of the cases of 1,068 patients were analyzed. The biochemical recurrence (BCR)-free survival was significantly worse in the patients who underwent PLND compared to those who did not (p=0.019). A multivariate analysis showed that high prostate-specific antigen (PSA) levels (p<0.001) and an advanced T-stage (p=0.018) were significant prognostic factors for BCR, whereas PLND had no effect on BCR (p=0.059). Thus, PLND in patients with prostate cancer whose Briganti score was 5% did not provide any oncological benefit. Further research is necessary to determine the indication criteria for conducting PLND.
The present invention relates to a method for preparing blood sugar-reducing, sleep-assisting and intestine-benefiting oral liquid with micron mulberry leaf powder, micron hawthorn powder, micron amber powder, micron picolinic acid chromium powder, fructo-oligosaccharide, micron pseudostellaria root powder and royal jelly dried powder. Raw material such as the micron mulberry leaf powder, the micron hawthorn powder, the micron amber powder, the micron picolinic acid chromium powder, the micron pseudostellaria root powder, the royal jelly dried powder, the fructo-oligosaccharide, etc. processed through high-technology airflow superfine grinding are combined and processed into the oral liquid. The oral liquid has the obvious function of reducing blood sugar and also has the effects of improving sleep quality, allaying fatigue, enhancing immunity, tranquilizing, improving eyesight, etc. The oral liquid can obtain scores of nutrient substances such as abundant protein, vitamins, mineral substances, active ferment, etc. and simultaneously has the functions of beautifying faces, keeping youthfulness, tranquilizing and reducing blood sugar because picolinic acid chromium which is extolled as a blood sugar reducing factor is added. Therefore, the present invention is a favorable method for preparing the oral liquid for protecting health and prolong life, and the oral liquid has Chinese characteristics and is especially designed for middle-aged diabetics and old diabetics all over the world.
Treatments were applied on the assigned marked sites on the lower back. Induction phase (21 days): left side, six treatment applications for 48 or 72 h. Challenge phase (five days): right side, one treatment application for 48 h.
In humans, the prevalence of congenital microphthalmia is estimated to be 0.2-3.0 for every 10,000 individuals, with nonocular involvement reported in ∼80% of cases. Inherited eye diseases have been widely and descriptively characterized in dogs, and canine models of ocular diseases have played an essential role in unraveling the pathophysiology and development of new therapies. A naturally occurring canine model of a syndromic disorder characterized by microphthalmia was discovered in the Portuguese water dog. As nonocular findings included tooth enamel malformations, stunted growth, anemia, and thrombocytopenia, we hence termed this disorder Canine Congenital Microphthalmos with Hematopoietic Defects. Genome-wide association study and homozygosity mapping detected a 2 Mb candidate region on canine chromosome 4. Whole-genome sequencing and mapping against the Canfam4 reference revealed a Short interspersed element insertion in exon 2 of the DNAJC1 gene (g.74,274,883ins[T70]TGCTGCTTGGATT). Subsequent real-time PCR-based mass genotyping of a larger Portuguese water dog population found that the homozygous mutant genotype was perfectly associated with the Canine Congenital Microphthalmos with Hematopoietic Defects phenotype. Biallelic variants in DNAJC21 are mostly found to be associated with bone marrow failure syndrome type 3, with a phenotype that has a certain degree of overlap with Fanconi anemia, dyskeratosis congenita, Shwachman-Diamond syndrome, Diamond-Blackfan anemia, and reports of individuals showing thrombocytopenia, microdontia, and microphthalmia. We, therefore, propose Canine Congenital Microphthalmos with Hematopoietic Defects as a naturally occurring model for DNAJC21-associated syndromes.
Placebo capsules for DS-01 will contain rice flour matched for color and texture in an identical outer capsule shell. Participants will be instructed to take 2 capsules daily for the duration of the trial.
The present invention relates to novel image registration. The rigid registration is based on a plurality of surfaces arranged in a 3D relationship in a cartesian coordinate system by fiducial markers. This registration process provides more accurate registration or requires smaller fiducial markers to achieve the same level of registration accuracy as compared to surface-based registration. Furthermore, the fiducial markers enable measurement of coordinates in the physical domain; thus, registration errors can be measured by comparing the coordinates of specific points in both the physical and virtual domains. This has potential application in comparing imaging physical to image (PI) or printing images to physical (IP) modalities, for example, for comparing the accuracy of 3D models created by computed tomography and optical scanners. Other potential applications also include assisting surgical navigation in dental implant placement. Thus, the proposed fiducial markers have potential developments in virtual reality applications.
This is a single arm clinical trial. The objective of the study is patients with recurrent or progressive leptomeningeal metastases from non-small cell lung cancer after leptomeningeal metastases-related treatment. The regimen of pemetrexed (Alimta, Eli Lilly and Company) is 10/15/20 mg, plus dexamethasone 5 mg, twice per week for 2 weeks, followed by once per week for 2-4 weeks. Pemetrexed and dexamethasone are administrated by intrathecal injection via lumbar puncture. Folic acid and vitamin B12 are administered to reduce the frequency of myelosuppression. Folic acid 200-400 μg is administered orally once daily, prior to the first intrathecal pemetrexed, until 21 days after the last intrathecal pemetrexed. A single dose of vitamin B12 1000 μg is administered by intramuscular injection before the first intrathecal pemetrexed，once per 3 weeks. To detect the pharmacokinetics of intrathecal pemetrexed, the serum and cerebrospinal fluid samples are collected. These samples would be analyzed by spectrometer for drug concentration.
A targeted approach is described for the production of biological recognition elements capable of fast, specific detection of anthrax spores on biosensor surfaces. Single chain antibodies (scFvs) are produced to EA1, a Bacillus anihracis S-layer protein that is also present, although is not identical, in related Bacillus species. These antibodies detect Bacillus anthracis EA1 protein and intact spores with a high degree of specificity, but do not detect other Bacillus species. Recombinant anti-EA1 scFvs were isolated from an B. anthracis immune library that contained antibody genes raised against B. anthracis spores and purified exosporium. Two approaches for scFv selection are disclosed; standard (non-competitive) panning, and competitive panning. The non-competitive bio-panning strategy isolated scFvs that recognised EA1 from B. anthracis, but also cross-reacted with other Bacillus species. In contrast, the competitive panning approach used S-layer proteins from otherBacillus species to compete out any cross reacting antibodies, generating scFvs that were highly specific to B. anthracis EA1 and demonstrated apparent nanomolar binding affinities. The specific, real time detection of B. anthracis spores was demonstrated with these scFvs by using an evanescent wave biosensor, the Resonant Mirror. The approach described here can be used to generate specific antibodies to any desired target where homologous proteins also exist in closely related species, and demonstrates clear advantages to using recombinant technology to produce biological recognition elements for detection of biological threat agents.
FIELD: oncology. SUBSTANCE: proposed preparation comprises, as active principal, LACTOFERRIN which is potent endogenic antioxidant. LACTOFERRIN is administered to patient in gelatin- immobilized form, whereby its contact with affected mucosa of oral cavity and esophagus is considerably prolonged. Proposed preparation exhibits antioxidant, antiinflammatory and antimicrobial effect; it is fully biocompatible with human organism. EFFECT: 1) significant positive clinical effect, namely: local radiation and chemio-radiation reactions are cut short in 80-90% patients in 3-10 days, i.e. 10-15 days faster than during treatment with vitaminized oils and dimexide; 2) prophylactic administration of preparation reduces by 50- 60% occurrence rate of local complications in oropharyngeal zone and esophagus of oncologic patients undergoing conservative antitumoral treatment. 2 cl, 1 tbl
OBJECTIVE: To investigate the efficacy of Longteng Tongluo recipe (, LTTL) combined with three-step analgesia for the treatment of lung cancer pain, and the changes in serum miRNA expressions before- and after treatment with LTTL and its correlation with lung cancer pain. The possible mechanism underlying LTTL effects on the treatment of lung cancer pain was conducted.
METHODS: The pilot study was conducted at the oncology ward of the Yueyang Hospital and the Longhua Hospital between March 2018 and October 2019. A prospective, single-blind, placebo controlled, randomized clinical trial of LTTL or placebo combined with three-step analgesia treatments were administered to 24 cancer pain patients diagnosed with lung cancer. Analgesic efficacy was investigated as the primary outcome. Equivalent morphine consumption and numerical rating scale (NRS) scores were used as the secondary outcome. In the present study, we utilized deep sequencing techniques to compare the differential miRNA expressions in serum samples obtained from two groups: the lung cancer pain treatment group (LTTL + three-step analgesia) and the control group (placebo + three-step analgesia). Next, we employed the target prediction database to investigate the target genes for differential miRNA expressions and Gene Ontology (GO) analysis along with Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis to examine the roles and the major biochemical and signaling pathways related to the differentially expressed target genes, respectively.
RESULTS: LTTL treatment significantly reduces the NRS score (P = 0.021) as compared to those before treatment, along with significant reductions in the total morphine equivalent consumption (P = 0.007) and the average daily equivalent morphine consumption (P = 0.003) as opposed to the control group. The expressions of 31 miRNAs differed considerably between the two groups of patients (≥ 2 times up-modulated or down-regulated between these groups, P<0.05). For instance, the miRNAs expression levels for patients before treatment (has-miR-2110 and has-miR-7d-3p) were significantly enhanced as compared to the healthy people, after LTTL treatment, the expressions of miR-2110 and miR-7d-3p in patients with lung cancer pain reduced significantly. Studies show that the above two miRNAs were significantly associated with lung cancer pain, which could mediate lung cancer pain. Furthermore, we identified 355 genes as potential targets of the 31 differentially expressed miRNAs. Pathway enrichment analyses using KEGG and GO analysis indicated that these target genes may play a crucial role in the development and modulation of lung cancer pain.
CONCLUSION: LTTL demonstrated a discernible impact on alleviating lung cancer pain and its mechanism of action may be related to the downregulation of has-miR-2110 and has-miR-7d-3p expressions. This pilot study provides support for further exploration of LTTL in patients with lung cancer pain.
PURPOSE:To obtain an antiulcer agent containing a specific benzimidazole derivative as an active component and having excellent activity to suppress gastric acid secretion and extremely high safety. CONSTITUTION:The benzimidazole derivative of formula I (R1 is H, lower alkyl, phenyl, etc.; R2 is H or lower alkyl; R1 and R2 may together with adjacent N from a ring; R3 and R4 are H, halogen, lower alkyl, etc.) is used as an antiulcer agent. The compound of formula I is a synthetic intermediate for the compound of formula I' which is known as an antiulcer agent, however, it has been found that the compound has excellent action to suppress secretion of gastric acid and is excellent as an antiulcer agent. Dose: preferably about 10-500mg daily by oral administration. The compound of formula I can be produced by reacting a 2-mercaptobenzimidazole compound of formula II with a 2-aminobenzyl compound of formula III.
INTRODUCTION: Positron emission tomography (PET) imaging can be used to evaluate arterial wall inflammation in extracranial vascular diseases. However, the application of PET imaging in unruptured intracranial aneurysms (UIA) remains unexplored. Our objective is to investigate feasibility of PET imaging using 18F-FDG and 68Ga-DOTANOC tracers to evaluate arterial wall inflammation in UIA.
METHODS AND ANALYSIS: This PET imaging feasibility study will enrol patients scheduled for surgical treatment of UIA. The study subjects will undergo PET imaging of the intracranial arteries within 1 month before planned surgery. The imaging protocol includes 18F-FDG PET MRI, MRA with gadolinium enhancement, and 68Ga-DOTANOC PET CT. The study will also involve preoperative blood samples, intraoperative cerebrospinal fluid (CSF) samples, and aneurysm sac biopsy. Planned sample size is at least 18 patients. Primary outcome is uptake of 18F-FDG or 68Ga-DOTANOC in intracranial arterial aneurysms compared with contralateral normal vessel as maximum standardised uptake value or target-to-blood pool ratio and correlation of uptake of 18F-FDG or 68Ga-DOTANOC to aneurysm histological findings. Secondary outcomes include estimating the correlations between uptake of 18F-FDG or 68Ga-DOTANOC and histological findings with blood and CSF miRNA-levels, arterial wall enhancement in gadolinium enhanced MRA, aneurysm size and shape, smoking, hypertension, and location of the aneurysm.
ETHICS AND DISSEMINATION: This study is approved by the Human Research Ethics Committee of the Hospital District of Southwest Finland, Finnish Medicines Agency Fimea, and Turku University Hospital. Findings will be disseminated through peer-reviewed journal articles and presentations at national and international conferences.
TRIAL REGISTRATION NUMBER: NCT04715503.
AIMS: Excessive neuroinflammation mediated mainly by microglia plays a crucial role in ischemic stroke. AZD1390, an ataxia telangiectasia mutated (ATM) specific inhibitor, has been shown to promote radio-sensitization and survival in central nervous system malignancies, while the role of AZD1390 in ischemic stroke remains unknown.
METHODS: Real-time PCR, western blot, immunofluorescence staining, flow cytometry and enzyme-linked immunosorbent assays were used to assess the activation of microglia and the release of inflammatory cytokines. Behavioral tests were performed to measure neurological deficits. 2,3,5-Triphenyltetrazolium chloride staining was conducted to assess the infarct volume. The activation of NF-κB signaling pathway was explored through immunofluorescence staining, western blot, co-immunoprecipitation and proximity ligation assay.
RESULTS: The level of pro-inflammation cytokines and activation of NF-κB signaling pathway was suppressed by AZD1390 in vitro and in vivo. The behavior deficits and infarct size were partially restored with AZD1390 treatment in experimental stroke. AZD1390 restrict ubiquitylation and sumoylation of the essential regulatory subunit of NF-κB (NEMO) in an ATM-dependent and ATM-independent way respectively, which reduced the activation of the NF-κB pathway.
CONCLUSION: AZD1390 suppressed NF-κB signaling pathway to alleviate ischemic brain injury in experimental stroke, and attenuated microglia activation and neuroinflammation, which indicated that AZD1390 might be an attractive agent for the treatment of ischemic stroke.
Following a 2-week run-in period for pump-setting adjustments and monitoring, participants 1 will use Fiasp insulin for 2 weeks, followed by Novolog insulin for 2 weeks. Both the subject and the investigator will be blinded to which group the subject is assigned.
Patients who are randomly allocated to this group will receive a drink made of anhydrous beet dextrose and pressurized whey protein in water (200 g/L + 100g/L). Patients will sip the drink for 4 hours of the 6 hour study.
The PH levels of a neonatal in his birth are an important factor in establishing the connection between events that occurred during the actual time of birth, to the risk of a significant morbidity development in the future. Gas values in cord blood are measurable and represent the condition of the fetus close to the time of birth. Their level is one of the essential criteria which are used to define acute hypoxic event during birth. As the oxygen supply to the fetus significantly disturbed, deficiency of oxygen in the tissues is growing. Therefore, the tissues begin to accumulate large amounts of acid and thereby developing fetal blood acidosis. Many works connected the presence of cord blood acidosis to development of neonatal cerebral palsy. According to the American Association of Obstetrics and Gynecology, cord blood gas sample is necessary when a prenatal event may be related (rightly or not) with negative neonatal outcome. This approach might be necessary when the case is legally controversial and there is a need to prove that umbilical cord gas values were normal at the pre-natal period.

Aim of study Our aim is to find the effect of the cord blood sample storage way, and the effect of the sample taking time from the delivery.